Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 2/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847001 | 0.87 | AKR1C3 (0.50) | L3MBTL1MTNR1AMTNR1BAOC3TDP1 | |
| SCHEMBL13184918 | 0.84 | MTNR1A (0.48) | L3MBTL1MTNR1AMTNR1BAOC3TDP1 | |
| SCHEMBL21217301 | 0.84 | L3MBTL1 (0.48) | L3MBTL1MTNR1AMTNR1BAOC3TDP1 | |
| SCHEMBL16229190 | 0.81 | MEN1 (0.44) | TDP1KCNQ2ROCK2 | |
| SCHEMBL19575667 | 0.77 | KMT2A (0.36) | KDM4E | |
| SCHEMBL23031177 | 0.77 | TDP1 (0.57) | L3MBTL1MTNR1AMTNR1BTDP1CASR | |
| SCHEMBL29201224 | 0.75 | L3MBTL1 (0.47) | L3MBTL1MTNR1AMTNR1BAOC3 | |
| SCHEMBL10245271 | 0.74 | AOC3 (0.48) | L3MBTL1AOC3CHRM2CHRM1CHRM3 | |
| SCHEMBL31359581 | 0.74 | GLS (0.55) | L3MBTL1MTNR1AMTNR1BAOC3GLS | |
| SCHEMBL6366469 | 0.73 | GLS (0.54) | L3MBTL1MTNR1AMTNR1BAOC3GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211675-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | EyePoint, Inc. | 2022-07-07 | — | — | US | disclosed |
| US-11253502-B2 | Tie-2 activators targeting the Schlemm's canal | EyePoint Pharmaceuticals, Inc. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200338048-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | EyePoint, Inc. | 2020-10-29 | — | — | US | disclosed |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-9949956-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180092883-A1 | PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-04-05 | — | — | US | disclosed |
| US-20180037579-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-20180022741-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-01-25 | — | — | US | disclosed |
| US-20180016245-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
| US-20180016245-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
| US-20130023542-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8329916-B2 | Human protein tyrosine phosphatase inhibitors and method of use | AERPIO THERAPEUTICS INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2012-05-24 | — | — | US | disclosed |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EyePoint, Inc. | 2012-05-24 | — | — | US | disclosed |
| US-20120077975-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHOD OF USE | EyePoint Pharmaceuticals, Inc. | 2012-03-29 | — | — | US | disclosed |
| US-8106078-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | WARNER CHILCOTT COMPANY, LLC (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | disclosed |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2011-09-01 | — | — | US | disclosed |
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | L3MBTL1 3091/4885MTNR1A 592/4885MTNR1B 685/4885 |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | L3MBTL1 1016/4885MTNR1A 1155/4885MTNR1B 1364/4885 |
| US-20220211675-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | TIE1, TEK, TGFB2 | L3MBTL1 4141/4885MTNR1A 1590/4885MTNR1B 823/4885 |
| US-20120077975-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHOD OF USE | PTPRCAP, PPP5C, PTPRO | L3MBTL1 3350/4885MTNR1A 4321/4885MTNR1B 3812/4885 |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | L3MBTL1 3001/4885MTNR1A 4321/4885MTNR1B 3877/4885 |
| US-20180016245-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | L3MBTL1 1026/4885MTNR1A 308/4885MTNR1B 552/4885 |
| US-11253502-B2 | Tie-2 activators targeting the Schlemm's canal | TIE1, TEK, TGFB2 | L3MBTL1 4141/4885MTNR1A 1590/4885MTNR1B 823/4885 |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | L3MBTL1 1026/4885MTNR1A 308/4885MTNR1B 552/4885 |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | L3MBTL1 1026/4885MTNR1A 308/4885MTNR1B 552/4885 |
| US-20200338048-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | TIE1, TEK, TGFB2 | L3MBTL1 4141/4885MTNR1A 1590/4885MTNR1B 823/4885 |
| US-20180037579-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | L3MBTL1 3091/4885MTNR1A 592/4885MTNR1B 685/4885 |
| US-20180022741-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | L3MBTL1 4715/4885MTNR1A 2436/4885MTNR1B 1098/4885 |
| US-20130023542-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | L3MBTL1 3001/4885MTNR1A 4321/4885MTNR1B 3877/4885 |
| US-20180092883-A1 | PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES | PPM1G, PPM1F, PPM1A | L3MBTL1 4731/4885MTNR1A 2994/4885MTNR1B 2378/4885 |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | L3MBTL1 3001/4885MTNR1A 4321/4885MTNR1B 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.